1Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage 111 primary breast cancer with primary chemotherapy, surgery and radia- tion therapy [ J ]. Cancer, 1988,62:2507 - 2516.
2Hortobagyi GN, Blumenschein GR, Spanos W, et al. Muhimodal treat -ment of locally ad- vanced breast cancer [ J]. Cancer, 1983,51 : 763 - 769.
6Maas AI, Menon DK, Lingsrna HF, et al. Re-orientation of clinical research in traumatic brain injury: report of an international work- shop on comparative effectiveness research [ J ]. J Neurotrauma, 2012,29( 1 ) :32-46.
7Tsertsvadze A, Maglione M, Chou R, et al. Updating comparative effectiveness reviews: current efforts in AHRQ's Effective Health Care Program [ J]. J Clin Epidemio1,2011,64 ( 11 ) : 1208-1215.
8Yue LQ. Regulatory considerations in the design of comparative observational studies using propensity scores [ J 1. J Biopharrn Stat, 2012,22 (6) : 1272-1279.
9Embi PJ, Tsevat J. Commentary: the relative research unit: provi- ding incentives for clinician participation in research activities [ J J. Acad Med ,2012,87 ( 1 ) :11-14.
10de Boer RH,Chan A,Tran B,et al. Use of non-anthracycline regi- mens in early stage breast cancer in Australia[ J]. Asia Pac J Clin 0ncol,2011,7 ( 1 ) :4-10.
